Multiple Myeloma, MM

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...

CRISPR Identifies Novel Therapeutic lncRNA for...

CMN Briefs

Aug. 20, 2024

Italian researchers have used CRISPR-Cas9 screening to identify long non-coding RNA (lncRNA) RP11-350G8.5 as a key oncogenic factor in multiple...

Clinical Trial Updates From the Gene-Editing Field...

CMN Clinical

Mar. 27, 2024

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

CRISPR Clinical Trial Updates From Caribou...

Apr. 5, 2023

In this week's clinical update, we look at recent news from Caribou Biosciences. The company's second gene-edited CAR-T cell therapy candidate,...

Clinical Roundup: Gene-Edited CAR T Therapies

Feb. 6, 2023

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Clinical Trial Update: Encouraging Safety and...

Feb. 1, 2023

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...

Clinical Update: FDA Upgrades Status for Two...

May. 4, 2022

This week's clinical update includes news from Allogene Therapeutics and Graphite Bio. The U.S. Food and Drug Administration (FDA) recently granted...

CRISPR Medicine in 2021 – What a Phenomenal Year...

Dec. 28, 2021

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...